Q-omics provides the consensus-scored ZDHHC12 profile across patient tissues and cancer cell-line models. ZDHHC12 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ZDHHC12 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, ZDHHC12 RNA expression shows 19,292 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, HNSC, and THYM as cancer lineages where ZDHHC12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZDHHC12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZDHHC12 survival associations across molecular data types. ZDHHC12 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZDHHC12 RNA expression–survival associations across cancer types. High ZDHHC12 expression shows unfavorable associations in UVM, ACC, UCS, LGG, BLCA and LIHC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ZDHHC12 RNA expression.
This table summarizes ZDHHC12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ZDHHC12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZDHHC12 shows higher tumor expression in HNSC, BLCA, LUSC, KIRP, LIHC and UCEC. The HNSC box plot shows higher ZDHHC12 RNA expression in tumor versus normal tissue (log2 FC = +1.204, t-test p < 0.001).
This table shows molecular features associated with ZDHHC12 in patient tissues and cancer cell lines. In patient samples, ZDHHC12 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZDHHC12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BLOOD_Leukemia.
